The addition of venetoclax to fludarabine, cytarabine, G‐CSF, and idarubicin (FLAG‐IDA) in R/R AML also translated into high response rates, including a composite complete response of 90% in newly diagnosed patients and 67% in R/R patients [25]. The gene discussed is CSF3; the disease is acute myeloid leukemia.